Helsinn Healthcare
As of the edition of 20 October 2026, Helsinn Healthcare runs 6 drugs, 3 of them marketed; it is on route A at 5 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Palonosetron | none listed | 3 |
| Infigratinib | Ends 2029 (patent) | 4 |
| Anamorelin | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 5 targets, route B at 5 targets.
All 10 rows on route A or B
In the product10 company-target rows on route A or B; 7 are not shown here, and no score is.
See all 10 targets where Helsinn Healthcare needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 6 trials led
- Blood and lymph: 5 trials led
- Lungs and airways: 2 trials led